|
Targeting the unmet medical need in Parkinson's Disease - the fastest growing neurological disorder. Sent on 15 April 2021
Gene therapies for body and brain in Duchenne Muscular Dystrophy, progress moves forward. Sent on 08 March 2020
Announcing Transpharmation Poland! Sent on 08 February 2020
Psilocybin: the power of mental reorganisation Sent on 06 December 2020
The future's bright for the magic mushroom. Expansion to world class premises Sent on 04 November 2020
We are delighted to share our very exciting news with you!In January 2021, Transpharmation Ltd will be taking on additional laboratory and office space, operating from the first-class facilities at the renowned Discovery Park research centre in Kent.This location will become Transpharmation’s primary site. Multiple therapeutic indications Sent on 05 October 2020
Transpharmation Ltd celebrate 10 years in business. See our latest neuroinflammation study being presented at the Annual Alzheimer's Drug Discovery Foundation conference. Focus on pain Sent on 04 September 2020
September is pain awareness month and we are presenting our latest pain study 'The effect of a reduced streptozocin dose and social housing on well-being, mechanical hypersensitivity and burrowing behaviour in type-1 diabetic rodents' at the IASP virtual conference. Getting back out there safely Sent on 04 August 2020
Parkinson's disease enterprise partnership Sent on 05 May 2020
Transpharmation business continuation reassurance.Sent on 23 March 2020
New service - PBMC's Sent on 11 March 2020
Transpharmation Ltd receive prestigious Horizon 2020 Grant Sent on 11 February 2020
Company of the year - you're in safe hands Sent on 16 January 2020
Advancing preclinical neuropathic pain research Sent on 10 December 2019
Welcome to News You Can Use - SfN special! Sent on 14 October 2019
Display #
Results 1 - 8 out of 8 |
- Can changes in EEG improve neuropathic pain treatments - read Oct newsletter.
- Nine posters ready to reveal at the SfN virtual conference 8-11 Nov, booth 1818.
- Joined-up preclinical and clinical trials to advance psilocybin drug development
- Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
- Announcing new premises in Poland with a focus on neuropsychiatric disorders...
- New state-of-the-art premises at Discovery Park, Kent
News you can use
Thanks for your interest in Transpharmation Ltd. We'd like to keep you updated on what's new and relevant. Please sign up to receive our newsletters, we won't bombard you or share your details with any other party and you can unsubscribe at any time.
Can changes in EEG improve neuropathic pain treatments? Sent on 11 October 2021
40Hz ASSR: sounds that change our thoughts about schizophrenia Sent on 31 August 2021
Clerkenwell Health and Transpharmation combine lab and human trials for psilocybin Sent on 09 August 2021
Translational endpoints for preclinical pain - improving your chances. Sent on 01 July 2021
Transpharmation aims for global standard. Let's talk about lab sustainability. Sent on 02 June 2021
- You are here:
-
Home
- Newsletter Archive
Our clients are our partners.
We work hard around the globe to create breakthrough results for them.
+48 515 244 120